Press Releases

  • || Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

    Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models. Data underscore potential of TAILWIND® platform to create unique CAR-NK treatments

      Full Press Release
  • || Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies

    Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio Inc., a contract development and manufacturing organization (CDMO) focused on cell and gene therapy, today announced their partnership to develop and manufacture Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors.

      Full Press Release
  • || MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

    MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies

      Full Press Release
  • || Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting

    CAMBRIDGE, Mass. – November 10, 2022 – Catamaran Bio, Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, today announced new data demonstrating preclinical efficacy of two CAR-NK cell therapies in solid and hematological cancers.

      Full Press Release
  • || Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting

    the company will present preclinical efficacy data for its allogeneic, cryopreserved CAR-NK cell therapies designed to treat solid tumors, engineered using Catamaran’s TAILWINDTM platform.

      Full Press Release
  • || Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors

    Two poster presentations at ASGCT Annual Meeting demonstrate potential of synthetic receptors to prevent TGFβ-mediated immunosuppression and enhance NK cell expansion and function

      Full Press Release
  • || Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Solid Tumors

    Two posters describe features of Catamaran’s CAR-NK platform designed to overcome the immunosuppressive effects of the solid tumor microenvironment

      Full Press Release
  • || Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer

    Experienced industry clinician brings deep expertise in oncology development including advancement of allogeneic cell therapy to first-in-human trials

      Full Press Release
  • || Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT 179, a HER2-targeted Allogeneic CAR-NK Cell Therapy

    CAT-179 significantly reduces tumor burden and extends survival in a mouse HER2+ xenograft model

      Full Press Release
  • || Catamaran Bio Appoints Frank Lee as Chair of its Board of Directors

    Appointment of experienced commercial leader brings significant expertise in solid tumor indications targeted by Catamaran’s CAR-NK programs

      Full Press Release
  • || Catamaran Bio Expands Collaboration for CAR-NK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies

    Next phase of collaboration to primarily focus on continued advancement of transposon engineering for allogeneic CAR-NK cell therapies and optimization of CAR-NK cell manufacturability

      Full Press Release
  • || Catamaran Bio to Present Preclinical Efficacy Data on Allogeneic Solid Tumor CAR-NK Program at AACR Annual Meeting 2022

    CAMBRIDGE, Mass. – March 9, 2022 – Catamaran Bio, Inc., a biotechnology company developing off ‑the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, today announced that the company will present preclinical efficacy data for its CAT-179 program, an allogeneic solid tumor CAR-NK cell therapy, at the American Association for Cancer Research (AACR) Annual Meeting […]

      Full Press Release
  • || Catamaran Bio Announces Appointment of Michael DeRidder, PhD, as Senior Vice President, Corporate Strategy and New Product Planning

    CAMBRIDGE, Mass. – February 28, 2022 – Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, today announced the appointment of Michael DeRidder, PhD, as Senior Vice President, Corporate Strategy and New Product Planning. Dr. DeRidder brings extensive experience leading product planning and portfolio strategy in the cell […]

      Full Press Release
  • || Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf CD70-Targeted CAR NK Cell Therapy for the Treatment of CD70-Expressing Cancers

    Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, today announced preclinical data that demonstrate key capabilities of its TAILWINDTM platform being applied to develop CAT-248, an allogeneic CD70‑targeted CAR-NK cell therapy.

      Full Press Release
  • || Catamaran Bio Announces Appointment of Tara Place as Vice President, Human Resources and Organizational Effectiveness

    CAMBRIDGE, Mass. – November 15, 2021 – Catamaran Bio, Inc., a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced the appointment of Tara Place, MBA, as Vice President, Human Resources and Organizational Effectiveness. Ms. Place brings more than 20 years of experience as a global human resources leader with broad experience […]

      Full Press Release
  • || Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data Presentation at ASH 2021

    Catamaran’s CAR-NK programs include CAT-179 targeting HER2-expressing breast and gastric cancers, and CAT-248 targeting CD70-expressing cancers

      Full Press Release
  • || Catamaran Bio Announces Scientific Advisory Board

    Catamaran Bio, Inc., a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced the formation of its scientific advisory board (SAB). The group is comprised of world-class cell therapy scientists and clinicians spanning research, manufacturing and clinical development. The SAB will work collaboratively with Catamaran’s leadership and R&D teams to help advance the company’s platform and its pipeline of CAR-NK cell therapies.

      Full Press Release
  • || Catamaran Bio Announces Appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing

    Catamaran Bio, Inc., a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced the appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing. Dr. Gold is a recognized leader with more than 25 years of experience in cell and gene therapy process development and GMP manufacturing.

      Full Press Release
  • || Catamaran Bio and Bio-Techne Announce Expanded Collaboration for CAR NK Cell Manufacturing Technologies

    Broadened agreement includes the development of novel technologies for allogeneic CAR-NK cell expansionCatamaran also secures broad worldwide license to TcBuster™ transposon system for clinical and commercial manufacturing of next generation cell therapies.

      Full Press Release
  • || Catamaran Bio’s Scientific Founder Leads Pivotal Advancements in Non-viral Engineering of CAR-NK Cells Using Novel Transposon Technology

    Transposon technology efficiently generates active CAR-NK cells and has potential advantages compared to viral approaches. Oral presentation highlighted at the American Society of Gene and Cell Therapy annual meeting

      Full Press Release
  • || Catamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer

    Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat patients with significant unmet medical need, today announced the appointment of Scott Holmes, MS, MBA, as Chief Financial Officer.

      Full Press Release
  • || Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer

    CAMBRIDGE, Mass. – February 4, 2021 – Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat diseases with significant unmet medical need, today announced the appointment of Alvin Shih, MD, MBA, as President and Chief Executive Officer. He has concurrently been appointed to the Board of Directors for Catamaran. Dr. Shih […]

      Full Press Release
  • || Catamaran Bio Launches with $42 Million Financing to Develop Off the Shelf CAR-NK Cell Therapies to Treat Solid Tumors

    Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in financing.

      Full Press Release